Jigsaw

Jigsaw Therapeutics is an Australian biotechnology company focused on the discovery and development of small molecule drugs that target protein-protein interactions (PPIs). The company specifically targets high-value oncogenic drivers that have historically been considered undruggable, with a primary focus on the MYC protein. By utilizing a proprietary discovery platform, Jigsaw aims to disrupt the complex molecular networks that drive cancer cell survival and proliferation. Currently in the pre-clinical stage, the company is advancing a pipeline of candidates designed to treat a variety of solid tumors and hematological malignancies. Jigsaw's approach integrates structural biology and medicinal chemistry to develop precision medicines for patients with significant unmet medical needs.